Interaction Color Code
Clinical Bottom Line
Administer standard doses
Drug 1
Drug 1 dose
150 mg elvitegravir / 150 mg cobicistat once daily
Drug 1 effect
Cmax decreased 13%; AUC decreased 6%; Cmin increased 8%
Drug 2
Drug 2 dose
400 / 100 mg once daily
Drug 2 effect
Velpatasvir Cmax increased 30%, AUC increased 50%, Cmin increased 60%; Sofosbuvir Cmax increased 23%, AUC increased 37%; Sofosbuvir metabolite Cmax increased 29%, AUC increased 48%, Cmin increased 58%
Clinical Effects
Stribild is coformulated with tenofovir disoproxil fumarate and TDF levels are increased by sofosbuvir / velpatasvir.
Management
Monitor TDF-related adverse reactions
Import ID
141
